Amplification and overexpression of prosaposin in prostate cancer

Genes Chromosomes and Cancer

Volumn 44, Issue 4, 2005, Pages 351-364

  Koochekpour, Shahriar ^a   Zhang, Yujun ^a   Beroukhim, Rameen ^b,c   Hsieh, Chia Ling ^d   Hofer, Matthias D ^b,e   Zhau, Haiyen E ^d   Hiraiwa, Masao ^f   Pattan, Daniel Y ^a   Ware, Joy L ^g   Luftig, Ronald B ^a   Sandhoff, Konrad ^h   Sawyers, Charles L ⁱ   Pienta, Kenneth J ^j   Rubin, Mark A ^b,e   Vessella, Robert L ^k   Sellers, William R ^b,c   Sartor, Oliver ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF BONN   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUROTROPHIC FACTOR; POLYCLONAL ANTIBODY; PROSAPOSIN; SPHINGOLIPID ACTIVATOR PROTEIN; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA LIBRARY; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; GONAD DEVELOPMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGEMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PSAP GENE; PUNCH BIOPSY; REAL TIME POLYMERASE CHAIN REACTION; SEMINAL PLASMA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHERN BLOTTING; SYSTEMATIC REVIEW; TUMOR XENOGRAFT; VISCERAL METASTASIS;

BLOTTING, WESTERN; CELL LINE, TUMOR; CLONING, MOLECULAR; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION; MALE; MICROARRAY ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAPOSINS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 26944466215     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20249     Document Type: Article

References (64)

1. Abdul M, Hoosein N. 2000. Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 5:168-172.
2. Achary PM, Zhao H, Fan Z, Gogineni S, Pulijaal VR, Herbst L, Mahadevia PS, Jones JG, Klinger HP, Vikram B. 2003. A candidate metastasis-associated DNA marker for ductal mammary carcinoma. Breast Cancer Res 5:R52-R58.
3. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. 2000. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 60:6134-6141.
4. Bav VL, Jackson-Cook CK, Broithman AR, Maygarden SJ, Ware JL. 1994. Tumorigenicity of SV40 Tantigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 58:721-729.
5. Campana WM, Hiraiwa M, O'Brien JS. 1998. Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 3:307-314.
6. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. 1994. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153-162.
7. Chung LWK, Gleave ME, Hsieh J-T, Hong S-J, Zhau HE. 1991. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormone responsiveness. Cancer Surv 11:91-121.
8. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. 2003. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55:239-246.
9. De La Taille A, Vacherot F, Salomon L, Druel C, Gil D, De Medina S, Abbou C, Chopin D. 2001. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 4:204-212.
10. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
11. Fujita N, Suzuki K, Vanier MT, Popka B, Maeda N, Klein A, Henseler M, Sandhoff K. 1996. Targeted disruption of the mouse sphingolipid activator gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 5:711-725.
12. Fukomoto M, Shevrin DH, Roninson IB. 1988. Analysis of gene amplification in human tumor cell lines. Proc Natl Acad Sci USA 85:6846-6850.
13. Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere RW, White F, Schroder H, Coffey DS. 1999. Future prospects in prostate cancer. Prostate 40:261-268.
14. Helenius MA, Saramaki OR, Linja MJ, Tammela TLJ, Visakorpi T 2001. Amplification of urokinase gene in prostate cancer. Cancer Res 61:5340-5344.
15. Henseler M, Klein A, Glombitza GJ, Suziki K, Sandhoff K. 1996. Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. J Biol Chem 271:8416-8423.
16. Hiraiwa M, Campana WM, Martin BM, O'Brien JS. 1997a. Prosaposin receptor: evidence for a G-protein associated receptor. Biochem Biophys Res Comm 240:415-418.
17. Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O'Brien JS. 1997b. Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentration in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Natl Acad Sci USA 94:4778-4781.
18. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. 2000. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:63-99.
19. Hwa V, Tomasini-Sprenger C, Bermejo AL, Rosenfeld RG, Plymate SR. 1998. Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells. J Clin Endocrinol Metab 83:4355-4362.
20. Kennedy GC, Matsuzaki H, Dong S, Liu WM, Huang J, Liu G, Su X, Cao M, Chen W, Zhang J, Liu W, Yang G, Di X, Ryder T, He Z, Surti U, Phillips MS, Boyce-Jacino MT, Fodor SR Jones KW. 2003. Large-scale genotyping of complex DNA. Nat Biotechnol 21:1233-1237.
21. Kessler B, Albertsen P. 2003. The natural history of prostate cancer. Urol Clin North Am 30:219-226.
22. Kishimoto Y, Hiraiwa M, O'Brien JS. 1992. Saposins: structure, function, distribution and molecular genetics. J Lipid Res 33:1255-1267.
23. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Stetler-Stevenson WG, Kaelin WG, Jr, Linehan WM, Klausner RD, Gnarra GR, Vande Woude GF. 1999. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19:5902-5912.
24. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee T-J, Hebert FE, Kao YS, Skinner J, Rayford W. 2004a. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60:141-152.
25. Koochekpour S, Sartor O, Lee T-J, Hebert F, Patten DY, Minokadeh A. 2004b. Prosaposin is a novel AR-target gene and upregulates AR/PSA expression in prostate stromal and cancer cells. J Urol 171:154-155.
26. Koochekpour S, Sartor O, Lee T-J, Zieske A, Patten DY, Hiraiwa M, Sandhoff K, Remmel N, Minokadeh A. 2004c. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate 61:114-123.
27. Koochekpour S, Sartor O, Hiraiwa M, Lee T-J, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY. 2005. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl 7:147-158.
28. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang ZF, Cordon-Cardo C. 1996. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 69:110-113.
29. Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. 2002. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 35:66-73.
30. Lee T-J, Sartor O, Lee T-J, Minokadeh A, Patten DY, Sun Y, Grabowski GA, Koochekpour S. 2004a. Differential induction of prosaposin promoter by androgen and serum in human prostate cancer and stromal cells. Proc Am Assoc Cancer Res 45:219-220.
31. Lee T-J, Sartor O, Luftig R, Koochekpour S. 2004b. Saposin C promotes survival and prevents apoptosis via P13K/Akt-dependent pathway in prostate cancer cells. Mol Cancer 3(1):31.
32. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. 2004. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20:1233-1240.
33. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
34. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TLJ, Vessella RL, Pavlimo JJ, Visakorpi T. 2004. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10:1032-1040.
35. Morales CR, Badran H. 2003. Prosaposin ablation inactivates the MAPK and Akt signaling pathways and interferes with the development of the prostate gland. Asian J Androl 5:57-63.
36. Morales CR, El-Alfy M, Zhao Q, Igdoura SA. 1996. Expression and tissue distribution of rat sulfated glycoprotein-1 (Prosaposin). J Histochem Cytochem 44:327-337.
37. Morales CR, Zhao Q, El-Alfy M, Suzuki K. 2000. Targeted disruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J Androl 21:765-775.
38. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP. 2001. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20:6718-6723.
39. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493-2500.
40. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T 1998a. Genetic alterations in prostate cancer ce 11 lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 101:53-57.
41. Nupponen NN, Kakkola L, Koivisio P, Visakorpi T 1998b. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148.
42. Nupponen NN, Wallen MJ, Ponciano D, Tobbins CM, Tammela TLJ, Vessella RL, Carpten JD, Visakorpi T. 2004. Mutational analysis of susceptibility genes RNASEL/HPC1, KLAC2/HPC2, and MSRI in sporadic prostate cancer. Genes Chromosomes Cancer 39:119-125.
43. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y. 1994. Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci USA 91:9593-9596.
44. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z. 2000. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res 60:6563-6567.
45. Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS, Carrol JM, Roberts CT, Jr, Ware JR. 2004. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 61:276-290.
46. Porrka KP, Visakorpi T 2004. Molecular mechanisms of prostate cancer. Eur Urol 45:683-691.
47. Rorman EG, Grabowski GA. 1989. Molecular cloning of a human co-beta-glucosidase cDNA: evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and rats. Genomics 5:486-492.
48. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM. 2004. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 64:3814-3822.
49. Sandhoff K, Kolter T. 2003. Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci 358:847-861.
50. Savinainen KJ, Linja MJ, Saramaki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T 2004. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer 90:1041-1046.
51. Schimke RT 1986. Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57:1912-1917.
52. Schnabel D, Schroder M, Furst W, Klein A, Hurwitz R, Zenk T, Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K. 1992. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem 267:3312-3315.
53. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Mac Vicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. 2004. Androgen-independent prostate cancer is a heterogenous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209-9216.
54. Sramkoski RM, Pretlow TG, II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. 1999. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35:403-409.
55. Stark GR. 1986. DNA amplification in drug resistant cells and in tumors. Cancer Surv 5:1-23.
56. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581.
57. Tripputi P, Blasi F, Verde P, Cannizzaro LA, Emanuel BS, Croce CMP. 1985. Human urokinase gene is located on the long arm of chromosome 10. Proc Natl Acad Sci USA 82:4448-4452.
58. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R. 2002. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 161:705-715.
59. Vielhaber G, Hurwitz R, Sandhoff K. 1996. Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP) precursor in cultured human fibroblasts. Mannose 6-phosphate receptor-independent of SAP precursor. J Biol Chem 271:32438-32446.
60. Wainstein MA, He F, Robinson D, Kung HJ, Schwartx S, Giaconia JM, Edgehouse NL, Pretlow TP, Bonder DR, Kursh ED. 1994. CWR22: androgen-dependent xenograft model derived from a primary human prostate carcinoma. Cancer Res 54:6049-6052.
61. Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, Chung LW. 2004. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 64:1589-1594.
62. Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM. 1994. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human Papillomavirus type 18 DNA. Cancer Res 54:5579-5583.
63. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. 2004. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 64:3060-3071.
64. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. 1996. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152-15157.